Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.

Shah, Manish A; Yoshino, Takayuki; Tebbutt, Niall C; Grothey, Axel; Tabernero, Josep; Xu, Rui-Hua; Cervantes, Andres; Oh, Sang Cheul; Yamaguchi, Kensei; Fakih, Marwan; Falcone, Alfredo; Wu, Christina; Chiu, Vi K; Tomasek, Jiri; Bendell, Johanna; Fontaine, Marilyn; Hitron, Matthew; Xu, Bo; Taieb, Julien; Van Cutsem, Eric

doi:10.1016/j.clcc.2022.11.002

Title

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.

Publication Date

2023-03

Author(s)

Shah, Manish A

Yoshino, Takayuki

Tebbutt, Niall C

Grothey, Axel

Tabernero, Josep

Xu, Rui-Hua

Cervantes, Andres

Oh, Sang Cheul

Yamaguchi, Kensei

Fakih, Marwan

Falcone, Alfredo

Wu, Christina

Chiu, Vi K

Tomasek, Jiri

Bendell, Johanna

Fontaine, Marilyn

Hitron, Matthew

Xu, Bo

Taieb, Julien

Van Cutsem, Eric

Subject

Clinical trial

Colon cancer

FOLFIRI

pSTAT3

phase 3

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1016/j.clcc.2022.11.002

Abstract

Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular antioxidant NAD(P)H:quinone oxidoreductase 1 that has been evaluated in various solid tumors, including metastatic colorectal cancer (mCRC). Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is hypothesized to predict response in napabucasin-treated patients with mCRC.

Link

link

Citation

Clinical Colorectal Cancer 2023-03; 22(1)

Jornal Title

Clinical Colorectal Cancer

ISSN

1938-0674

Austin Health

Files: